Due to its benefits, such as high selectivity, high sensitivity, rapid response, and low background signal [9,10], the ECL immunoassay has thus developed into a potent analytical tool for the highly specific and sensitive detection of cancer biomarkers such as CEA and prostate-specific antigen (PSA). Here, KLK3 is linked to cancer.